This is a prospective, single-center, open-label, two-cohort clinical study evaluating the safety, tolerability, biodistribution, radiation dosimetry, and diagnostic performance of [68Ga]Ga-ELI411 PET imaging in adult patients with solid tumors. Eligible patients with an indication for 18F-FDG PET imaging will receive a single intravenous administration of [68Ga]Ga-ELI411 followed by serial PET imaging. Imaging findings will be compared with conventional imaging, histopathology, and clinical follow-up when applicable. The study will also evaluate tracer biodistribution, radiation dosimetry, and lesion detection performance compared with standard 18F-FDG PET imaging.
Inclusion Criteria:
Exclusion Criteria:
Participants will receive a single intravenous administration of \[68Ga\]Ga-ELI411 followed by serial PET imaging for evaluation of biodistribution, radiation dosimetry, safety and diagnostic performance.
Wuhan, Hubei, China
Clinical Evaluation of [68Ga]Ga-FFD PET Imaging in Healthy Volunteers and Patients With Solid Tumors
A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
Clinical Application of FAP-Targeted Radionuclide Imaging in the Diagnosis and Staging of Malignant Solid Tumors
Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor
68Ga-HX01 PET in Healthy Volunteers and Malignant Tumors Patients